TRIL insider filings
Trillium Therapeutics Inc. — 36 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2021-11-19. Screen TRIL transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for TRIL between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Trillium Therapeutics Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2021-11-19 | 4 | Harrison Rosemary — See Remarks | Disposition to issuer (D): 75 · Disposition to issuer (D): 180,000 (derivative) @ $0 | EDGAR |
| 2021-11-19 | 4 | Parsons James T. — Chief Financial Officer | Disposition to issuer (D): 180,000 (derivative) @ $0 · Disposition to issuer (D): 94,792 (derivative) @ $0 · Disposition to issuer (D): 59,896 (derivative) @ $0 · Disposition to issuer (D): 5,761 (derivative) @ $0 · Disposition to issuer (D): 36,204 (derivative) @ $0 · Disposition to issuer (D): 24,390 (derivative) @ $0 · +2 more | EDGAR |
| 2021-11-19 | 4 | Looker Benjamin — General Counsel | Disposition to issuer (D): 190,000 (derivative) @ $0 | EDGAR |
| 2021-11-19 | 4 | MACKEY CATHERINE J — Director | Disposition to issuer (D): 67,000 (derivative) @ $0 | EDGAR |
| 2021-11-19 | 4 | Bruns Ingmar — Chief Medical Officer | Disposition to issuer (D): 400,000 (derivative) @ $0 | EDGAR |
| 2021-11-19 | 4 | Petrova Penka — Chief Development Officer | Disposition to issuer (D): 38,808 (derivative) @ $0 · Disposition to issuer (D): 4,574 (derivative) @ $0 · Disposition to issuer (D): 49,480 (derivative) @ $0 · Disposition to issuer (D): 83,960 (derivative) @ $0 · Disposition to issuer (D): 140,000 (derivative) @ $0 | EDGAR |
| 2021-11-19 | 4 | Uger Robert — Chief Scientific Officer | Disposition to issuer (D): 102,083 (derivative) @ $0 · Disposition to issuer (D): 58,333 (derivative) @ $0 · Disposition to issuer (D): 5,260 (derivative) @ $0 · Disposition to issuer (D): 23,473 (derivative) @ $0 · Disposition to issuer (D): 29,073 (derivative) @ $0 · Disposition to issuer (D): 250,000 (derivative) @ $0 | EDGAR |
| 2021-11-19 | 4 | TAYTON-MARTIN HELEN KATRINA — Director | Disposition to issuer (D): 40,000 (derivative) @ $0 · Disposition to issuer (D): 498,294.29 (derivative) | EDGAR |
| 2021-11-19 | 4 | Skvarka Jan — President and CEO, Director | Disposition to issuer (D): 197,000 (derivative) @ $0 · Disposition to issuer (D): 1,162,500 (derivative) @ $0 · Disposition to issuer (D): 600,000 (derivative) @ $0 | EDGAR |
| 2021-11-19 | 4 | Walker Paul Edward — Director | Disposition to issuer (D): 5,736,363 @ $0 · Disposition to issuer (D): 850,000 (derivative) @ $0 · Disposition to issuer (D): 6,750,000 (derivative) @ $0 · Disposition to issuer (D): 5,400,000 (derivative) @ $0 · Disposition to issuer (D): 40,000 (derivative) @ $0 | EDGAR |
| 2021-11-19 | 4 | Kamarck Michael E. — Director | Disposition to issuer (D): 67,000 (derivative) @ $0 | EDGAR |
| 2021-11-19 | 4 | Pucci Paolo — Director | Disposition to issuer (D): 67,000 (derivative) @ $0 | EDGAR |
| 2021-11-19 | 4 | Myers Scott Dunseth — Director | Disposition to issuer (D): 67,000 (derivative) @ $0 | EDGAR |
| 2021-11-19 | 4 | BESHAR LUKE M — Director | Disposition to issuer (D): 40,000 (derivative) @ $0 · Disposition to issuer (D): 6,666 (derivative) @ $0 · Disposition to issuer (D): 547,656.26 (derivative) | EDGAR |
| 2021-07-09 | 4 | Uger Robert — Chief Scientific Officer | Option exercise (M): 3,646 @ $0.30 · Sale (S): 3,646 @ $9 · Option exercise (M): 3,646 (derivative) @ $0 | EDGAR |
| 2021-07-02 | 4 | MACKEY CATHERINE J — Director | Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2021-06-09 | 4 | Uger Robert — Chief Scientific Officer | Option exercise (M): 3,646 @ $0.32 · Sale (S): 3,646 @ $8.27 · Option exercise (M): 3,646 (derivative) @ $0 | EDGAR |
| 2021-05-13 | 4 | Skvarka Jan — President and CEO, Director | Option exercise (M): 87,500 @ $0.45 · Option exercise (M): 19,198 @ $0.31 · Sale (S): 106,698 @ $9.20 · Option exercise (M): 23,802 @ $0.31 · Sale (S): 23,802 @ $9.24 · Option exercise (M): 87,500 (derivative) @ $0 · +2 more | EDGAR |
| 2021-05-11 | 4 | Uger Robert — Chief Scientific Officer | Option exercise (M): 3,646 @ $0.31 · Sale (S): 3,646 @ $9.30 · Option exercise (M): 3,646 (derivative) @ $0 | EDGAR |
| 2021-05-05 | 4 | Looker Benjamin — General Counsel | Grant/award (A): 190,000 (derivative) @ $0 | EDGAR |
| 2021-05-05 | 4 | Myers Scott Dunseth — Director | Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2021-04-09 | 4 | Uger Robert — Chief Scientific Officer | Option exercise (M): 3,646 @ $0.30 · Sale (S): 3,646 @ $10.82 · Option exercise (M): 3,646 (derivative) @ $0 | EDGAR |
| 2021-04-09 | 4 | Petrova Penka — Chief Development Officer | Option exercise (M): 2,708 @ $0.30 · Option exercise (M): 2,604 @ $3.36 · Sale (S): 5,312 @ $11.09 · Option exercise (M): 2,708 (derivative) @ $0 · Option exercise (M): 2,604 (derivative) @ $0 | EDGAR |
| 2021-03-15 | 4 | Uger Robert — Chief Scientific Officer | Option exercise (M): 2,917 @ $3.39 · Sale (S): 2,917 @ $11.97 · Option exercise (M): 2,917 (derivative) @ $0 | EDGAR |
| 2021-03-12 | 4 | Petrova Penka — Chief Development Officer | Option exercise (M): 2,708 @ $0.30 · Option exercise (M): 2,604 @ $3.35 · Sale (S): 5,312 @ $11.08 · Option exercise (M): 2,708 (derivative) @ $0 · Option exercise (M): 2,604 (derivative) @ $0 | EDGAR |
| 2021-03-10 | 4 | Uger Robert — Chief Scientific Officer | Option exercise (M): 3,646 @ $0.30 · Sale (S): 3,646 @ $10.11 · Option exercise (M): 3,646 (derivative) @ $0 | EDGAR |
| 2021-02-10 | 4 | Petrova Penka — Chief Development Officer | Option exercise (M): 2,708 @ $0.30 · Option exercise (M): 2,604 @ $3.31 · Sale (S): 5,312 @ $12.65 · Option exercise (M): 508 @ $9.62 · Sale (S): 508 @ $14.17 · Option exercise (M): 2,708 (derivative) @ $0 · +2 more | EDGAR |
| 2021-02-10 | 4 | Uger Robert — Chief Scientific Officer | Option exercise (M): 3,646 @ $0.30 · Option exercise (M): 2,917 @ $3.31 · Sale (S): 6,563 @ $12.65 · Option exercise (M): 584 @ $9.62 · Sale (S): 584 @ $14.12 · Option exercise (M): 3,646 (derivative) @ $0 · +2 more | EDGAR |
| 2021-01-15 | 4 | Skvarka Jan — President and CEO, Director | Option exercise (M): 5,419 @ $0.42 · Sale (S): 5,419 @ $15.04 · Option exercise (M): 19,581 @ $0.43 · Sale (S): 19,581 @ $15.03 · Option exercise (M): 5,419 (derivative) @ $0 · Option exercise (M): 19,581 (derivative) @ $0 | EDGAR |
| 2021-01-13 | 4 | Uger Robert — Chief Scientific Officer | Option exercise (M): 584 @ $9.57 · Sale (S): 584 @ $15.20 · Option exercise (M): 584 (derivative) @ $0 | EDGAR |
| 2021-01-13 | 4 | Petrova Penka — Chief Development Officer | Option exercise (M): 508 @ $9.57 · Sale (S): 508 @ $15.21 · Option exercise (M): 508 (derivative) @ $0 | EDGAR |
| 2021-01-12 | 4 | Parsons James T. — Chief Financial Officer | Option exercise (M): 8,505 @ $7.24 · Sale (S): 8,505 @ $15.79 · Option exercise (M): 8,505 (derivative) @ $0 | EDGAR |
| 2021-01-12 | 4 | Uger Robert — Chief Scientific Officer | Option exercise (M): 5,600 @ $11.01 · Sale (S): 5,600 @ $15.82 · Option exercise (M): 2,917 @ $3.33 · Sale (S): 2,917 @ $15.51 · Option exercise (M): 5,600 (derivative) @ $0 · Option exercise (M): 2,917 (derivative) @ $0 | EDGAR |
| 2021-01-12 | 4 | Petrova Penka — Chief Development Officer | Option exercise (M): 2,604 @ $3.33 · Sale (S): 2,604 @ $15.50 · Option exercise (M): 2,604 (derivative) @ $0 | EDGAR |
| 2021-01-11 | 4 | Petrova Penka — Chief Development Officer | Option exercise (M): 2,708 @ $0.30 · Sale (S): 2,708 @ $14.71 · Option exercise (M): 2,708 (derivative) @ $0 | EDGAR |
| 2021-01-11 | 4 | Uger Robert — Chief Scientific Officer | Option exercise (M): 3,646 @ $0.30 · Sale (S): 3,646 @ $14.75 · Option exercise (M): 3,646 (derivative) @ $0 | EDGAR |
Recent 8-K events — Trillium Therapeutics Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2021-11-17 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-11-16 | 8-K | 8.01 — Other Events | EDGAR |
| 2021-10-29 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-10-27 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-10-20 | 8-K | 8.01 — Other Events | EDGAR |
| 2021-10-15 | 8-K | 8.01 — Other Events | EDGAR |
| 2021-10-13 | 8-K | 8.01 — Other Events | EDGAR |
| 2021-08-23 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.01 — Changes in Control of Registrant 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-06-30 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TRIL returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs